The glucagon component can transiently raise blood glucose before the GLP-1 and GIP components bring it back down
Image Credit: azimmytws / Shutterstock.com A recent BMJ study determines whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists by type 2 diabetes (T2D) patients increases the risk of self-harm, suicidal ideation, and suicide as compared to patients prescribed dipeptidyl peptidase-4 (DPP-4) or sodium-glucose cotransporter-2 (SGLT-2) inhibitors
We may accept, reject, limit, place on hold, or cancel an order before shipment, including for inventory issues, pricing errors, suspected fraud, regulatory concerns, suspected prohibited use, incomplete verification, payment problems, or shipping restrictions
Patients and healthcare providers should be vigilant for the following serious adverse reactions: Low Blood Sugar (Hypoglycemia) : Particularly in patients with type 2 diabetes who are also taking medications for their diabetes, there is a risk of hypoglycemia
Possible side effects include: Mild redness or swelling in the treated area Temporary peeling, flaking, or crusting as damaged skin sheds Increased light sensitivity for several days after treatment Tenderness similar to a mild sunburn These effects usually resolve within one to two weeks and rarely interfere with daily activities
Like semaglutide and tirzepatide, the active ingredient in Saxenda liraglutide regulates the appetite
